Huo Xueyun, Li Zhenkun, Zhang Shuangyue, Li Changlong, Guo Meng, Lu Jing, Lv Jianyi, Du Xiaoyan, Chen Zhenwen
Department of Medical Genetics, School of Basic Medical Science, Capital Medical University, Beijing 100069, P.R. China.
Oncol Lett. 2017 Oct;14(4):4339-4348. doi: 10.3892/ol.2017.6721. Epub 2017 Aug 4.
Tumorigenesis is often caused by somatic mutation or epigenetic changes in genes that regulate aspects of cell death, proliferation and survival. Although the functions of multiple tumor suppressor genes have been well studied in isolation, how these genes cooperate during the progression of a single tumor remains unclear in numerous cases. The present study used N-methyl-N-nitrosourea (MNU), one of the most potent mutagenic nitrosourea compounds, to induce thymic lymphoma in C57BL/6J mice. Subsequently, the protein expression levels of phosphatase and tensin homolog (PTEN), transformation protein 53 and mutS homolog 2 (MSH2) were evaluated concomitantly in the thymus, liver, kidney and spleen of MNU-treated mice by western blotting. To determine whether changes in expression level were due to aberrant epigenetic regulation, the present study further examined the methylation status of each gene by MassARRAY analysis. During the tumorigenesis process of an MNU-induced single thymic lymphoma, the expression level of PTEN was revealed to be reduced in thymic lymphoma samples but not in normal or non-tumor thymus tissue samples. Furthermore, a marked reduction of P53 expression levels were demonstrated in thymic lymphomas and spleens with a metastatic tumor. Conversely, MSH2 upregulation was identified only in liver, kidney, and spleen samples that were infiltrated by thymic lymphoma cells. Furthermore, the present study revealed that a number of 5'-C-phosphate-G-3' sites located in the promoter of aberrantly expressed genes had significantly altered methylation statuses. These results improve the understanding of the course of mutagen-induced cancer, and highlight that epigenetic regulation may serve an important function in cancer.
肿瘤发生通常是由调节细胞死亡、增殖和存活等方面的基因发生体细胞突变或表观遗传变化引起的。尽管多个肿瘤抑制基因的功能已被单独深入研究,但在许多情况下,这些基因在单个肿瘤进展过程中如何协同作用仍不清楚。本研究使用N-甲基-N-亚硝基脲(MNU),一种最有效的诱变亚硝基脲化合物,在C57BL/6J小鼠中诱导胸腺淋巴瘤。随后,通过蛋白质印迹法同时评估MNU处理小鼠的胸腺、肝脏、肾脏和脾脏中磷酸酶和张力蛋白同源物(PTEN)、转化蛋白53和错配修复蛋白2(MSH2)的蛋白质表达水平。为了确定表达水平的变化是否是由于异常的表观遗传调控引起的,本研究进一步通过MassARRAY分析检查了每个基因的甲基化状态。在MNU诱导的单个胸腺淋巴瘤的肿瘤发生过程中,发现PTEN的表达水平在胸腺淋巴瘤样本中降低,但在正常或非肿瘤胸腺组织样本中未降低。此外,在有转移瘤的胸腺淋巴瘤和脾脏中,P53表达水平显著降低。相反,仅在被胸腺淋巴瘤细胞浸润的肝脏、肾脏和脾脏样本中发现MSH2上调。此外,本研究表明,位于异常表达基因启动子中的一些5'-C-磷酸-G-3'位点的甲基化状态发生了显著改变。这些结果增进了对诱变剂诱导癌症过程的理解,并突出了表观遗传调控在癌症中可能发挥重要作用。